A comparative study of bronchodilator response: utilizing pre-bronchodilator versus predicted normal values.

BMC Pulm Med

Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Miami, Miller School of Medicine, 1951 NW 7th Avenue, 33146, Miami, FL, USA.

Published: January 2024

Background: A positive bronchodilator response has been defined as a 12% increase in the forced expiratory volume in one second (FEV) or forced vital capacity (FVC) from their respective pre-bronchodilator values, combined with at least a 0.2 L absolute change. Recent recommendations suggested the use of the percent change in FEV and FVC relative to their predicted normal values without having applied them in patients with airflow obstruction. The aim of the current study was to compare the two approaches over a wide range of pre-bronchodilator FEV and FVC values.

Methods: A retrospective review of consecutive patients undergoing spirometry and bronchodilator testing was completed. The change in FEV and FVC with a bronchodilator was expressed relative to the pre-bronchodilator and predicted normal FEV and FVC.

Results: In 1,040 patients with a non-paradoxical change in FEV, 19.0% had a ≥ 12% change in FEV using their pre-bronchodilator value compared to 5.7% using their predicted normal value. For FVC, the respective values were 12.7% vs. 5.8%. The difference was retained in patients with a ≥ 0.2 L change in FEV or FVC. In unobstructed patients, the upper threshold (two standard deviations above the mean) of the bronchodilator response was 14% for FEV and 10% for FVC using predicted normal values.

Conclusions: Expressing the percent change in FEV and FVC relative to predicted normal values reduces the over-estimation of the bronchodilator response, especially in patients with a very low pre-bronchodilator FEV1, including in those with a ≥ 0.2 L change in FEV. Irrespective of pre-bronchodilator values, a ≥ 14% change in FEV and ≥ 10% change in FVC relative to the predicted normal values could be considered a positive bronchodilator response.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10809550PMC
http://dx.doi.org/10.1186/s12890-024-02859-4DOI Listing

Publication Analysis

Top Keywords

change fev
32
predicted normal
28
bronchodilator response
20
fev fvc
20
normal values
16
fev
12
fvc relative
12
relative predicted
12
change
10
fvc
9

Similar Publications

Background: Along with lung volume reduction surgery (LVRS), bronchoscopic lung volume reduction is a treatment option for end-stage emphysema. However, comparisons among interventions remain insufficient.

Methods: We searched on PubMed, CENTRAL, Embase, and Web of Science.

View Article and Find Full Text PDF

Background: Hypoxic pulmonary vasoconstriction leads to an increase in pulmonary artery pressure (PAP) and potentially right heart failure in healthy individuals and patients with respiratory diseases. Previous studies in patients with chronic obstructive pulmonary disease (COPD) exposed to hypobaric hypoxia have shown an increase in PAP, while traditional echocardiographic parameters revealed only minimal changes at high altitude. Speckle-tracking-derived analysis is potentially more sensitive to assess right ventricular (RV) function and we used this method to investigate the impact on RV function of patients with COPD ascending to high altitude and compared the results with the traditional echocardiographic parameters.

View Article and Find Full Text PDF

Background: The goal of cystic fibrosis transmembrane conductance regulator (CFTR) modulators is to reach normal CFTR function in people with cystic fibrosis. Vanzacaftor-tezacaftor-deutivacaftor restored CFTR function in vitro and in phase 2 trials in participants aged 18 years and older resulting in improvements in CFTR function, as measured by sweat chloride concentrations and lung function as measured by spirometry. We aimed to evaluate the efficacy and safety of vanzacaftor-tezacaftor-deutivacaftor compared with standard of care elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older.

View Article and Find Full Text PDF

Background/objectives: Both aging and chronic obstructive pulmonary disease (COPD) are strongly associated with changes in the metabolome; however, it is unknown whether there are common aging/COPD metabolomic signatures and if accelerated aging is associated with COPD.

Methods: Plasma from 5704 subjects from the Genetic Epidemiology of COPD study (COPDGene) and 2449 subjects from Subpopulations and intermediate outcome measures in COPD study (SPIROMICS) were profiled using the Metabolon global metabolomics platform (1013 annotated metabolites). Post-bronchodilator spirometry measures of airflow obstruction (forced expiratory volume at one second (FEV)/forced vital capacity (FVC) < 0.

View Article and Find Full Text PDF

Changes in muscle-to-fat ratio are associated with lung function decline and airflow obstruction in the general population.

Respir Res

December 2024

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.

Background: The long-term relationship between body composition and lung function has not yet been fully demonstrated. We investigated the longitudinal association between muscle-to-fat (MF) ratio and lung function among middle-aged general population.

Methods: Participants were enrolled from a community-based prospective cohort between 2005 and 2014.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!